Stock CNSP CNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Real-time Estimate Cboe BZX
Other stock markets
 08:50:04 20/06/2024 pm IST 		5-day change 1st Jan Change
2.195 USD -9.30% Intraday chart for CNS Pharmaceuticals, Inc. -39.78% -96.57%
14/06 CNS Pharmaceuticals, Inc. announced that it expects to receive $1.3725 million in funding CI
10/06 Sector Update: Health Care Stocks Advance Late Afternoon MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Afternoon
MT
CNS Pharmaceuticals Files Registration Statement for $9.2 Million Share, Warrant Offering -- Shares Fall
MT
CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week
MT
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings
MT
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme
CI
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
CI
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland
CI
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme
CI
CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme
CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
CNS Pharmaceuticals, Inc. Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of Gbm with First Patient Enrolled in Switzerland
CI
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug
RE
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CNSP Stock
  4. News CNS Pharmaceuticals, Inc.
  5. Highlights